SARS-Cov2 variants and convalescent plasma: reality, fallacies, and opportunities
Arturo Casadevall, … , Michael Joyner, Liise-anne Pirofski
Arturo Casadevall, … , Michael Joyner, Liise-anne Pirofski
Published February 23, 2021
Citation Information: J Clin Invest. 2021. https://doi.org/10.1172/JCI148832.
View: Text | PDF
Viewpoint In-Press Preview

SARS-Cov2 variants and convalescent plasma: reality, fallacies, and opportunities

Abstract

In recent months genomic characterization of pandemic SARS-CoV-2 isolates identified viral variants that are less susceptible to neutralization by convalescent plasma (CP), vaccine-elicited plasma/sera, or SARS-CoV-2 monoclonal antibodies than earlier SARS-CoV-2 strains. In this Viewpoint, Casadevall et al. argue against the causal association made in some press articles between the emergence of SARS-CoV-2 variants and convalescent plasma use.

Authors

Arturo Casadevall, Jeffrey Henderson, Michael Joyner, Liise-anne Pirofski

×

Full Text PDF | Download (90.69 KB)